Tumor budding in colorectal carcinoma: Confirmation of prognostic significance and histologic cutoff in a population-based cohort

American Journal of Surgical Pathology

Volumn 39, Issue 10, 2015, Pages 1340-1346

  Graham, Rondell P ^a   Vierkant, Robert A ^a   Tillmans, Lori S ^a   Wang, Alice H ^a   Laird, Peter W ^b   Weisenberger, Daniel J ^c   Lynch, Charles F ^d   French, Amy J ^a   Slager, Susan L ^a   Raissian, Yassaman ^a   Garcia, Joaquin J ^a   Kerr, Sarah E ^a   Lee, Hee Eun ^a   Thibodeau, Stephen N ^a   Cerhan, James R ^a   Limburg, Paul J ^a   Smyrk, Thomas C ^a  

^a MAYO CLINIC   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Bud count; Colorectal carcinoma; Cutoff; KRAS; Poor prognosis; Tumor budding

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

AGED; BIOPSY; CANCER STAGING; CARCINOMA; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DIAGNOSIS; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; OBSERVER VARIATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; OBSERVER VARIATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84941798502     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000504     Document Type: Article

References (38)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191-197.
2. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627-635.
3. Mitrovic B, Schaeffer DF, Riddell RH, et al. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25: 1315-1325.
4. Gospodarowickz MK, O'Sullivan B, Sobin LH. Prognostic Factors in Cancer. New York: Wiley-Liss; 2006.
5. Jass JR, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol. 2003;56:69-73.
6. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46: 1400-1406.
7. Ueno H, Price AB, Wilkinson KH, et al. A new prognostic staging system for rectal cancer. Ann Surg. 2004;240:832-839.
8. Zlobec I, Minoo P, Terraciano L, et al. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology. 2011;59:482-495.
9. Folsom AR, Kaye SA, Prineas RJ, et al. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990;131:794-803.
10. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117-1121.
11. Bisgard KM, Folsom AR, Hong CP, et al. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol. 1994;139:990-1000.
12. Zhang S, Folsom AR, Sellers TA, et al. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer. 1995;76:275-283.
13. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005;14:133-137.
14. Limburg PJ, Vierkant RA, Cerhan J, et al. Cigarette smoking and colorectal cancer: long-term, subsite-specific risks in a cohort study of postmenopausal women. Clin Gastroenterol Hepatol. 2003;1: 202-210.
15. Samadder NJ, Vierkant RA, Tillmans LS, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology. 2013;145:348-356. e1-2.
16. Eilers PH, Marx BD. Flexible smoothing with B-splines and penalties. Stat Sci. 1996;11:89-121.
17. Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25(2B):1269-1272.
18. Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treatment. 2005;37:177-182.
19. Ishikawa Y, Akishima-Fukasawa Y, Ito K, et al. Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer. 2008;112:924-933.
20. Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008;10:41-47.
21. Losi L, Ponti G, Gregorio CD, et al. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract. 2006;202:663-670.
22. Morodomi T, Isomoto H, Shironzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539-543.
23. Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127-132.
24. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134-141.
25. Yamauchi H, Togashu K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905-910.
26. Karamitopoulou E, Zlobec I, Kolze V, et al. Proposal for a 10-highpower-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 2013;26:295-301.
27. Zlobec I, Bihl MP, Foerster A, et al. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology. 2012;61:777-787.
28. Choi HJ, Park KJ, Shu JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis. 2007;22:863-868.
29. Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568-572.
30. Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42-47.
31. Zlobec I, Molinari F, Martin V, et al. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol. 2010;16:4823-4831.
32. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50:151-162.
33. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer. 2012;106: 1713-1717.
34. Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382-1392.
35. Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601-1607.
36. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17-24.
37. Sy J, Fung CL, Dent OF, et al. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum. 2010;53:301-307.
38. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.